Advertisement

Journal of Molecular Medicine

, Volume 93, Issue 6, pp 619–631 | Cite as

Retargeting pre-existing human antibodies to a bacterial pathogen with an alpha-Gal conjugated aptamer

  • Sascha A. Kristian
  • John H. Hwang
  • Bradley Hall
  • Emma Leire
  • John Iacomini
  • Robert Old
  • Uri Galili
  • Charles Roberts
  • Kary B. Mullis
  • Mike WestbyEmail author
  • Victor NizetEmail author
Original Article

Abstract

The ever-increasing threat of multi-drug resistant bacterial infections has spurred renewed interest in alternative approaches to classical antibiotic therapy. In contrast to other mammals, humans do not express the galactose-α-1,3-galactosyl-β-1,4-N-acetyl-glucosamine (α-Gal) epitope. As a result of exposure of humans to α-Gal in the environment, a large proportion of circulating antibodies are specific for the trisaccharide. In this study, we examine whether these anti-Gal antibodies can be recruited and redirected to exert anti-bacterial activity. We show that a specific DNA aptamer conjugated to an α-Gal epitope at its 5′ end, herein termed an alphamer, can bind to group A Streptococcus (GAS) bacteria by recognition of a conserved region of the surface-anchored M protein. The anti-GAS alphamer was shown to recruit anti-Gal antibodies to the streptococcal surface in an α-Gal-specific manner, elicit uptake and killing of the bacteria by human phagocytes, and slow growth of invasive GAS in human whole blood. These studies provide a first in vitro proof of concept that alphamers have the potential to redirect pre-existing antibodies to bacteria in a specific manner and trigger an immediate antibacterial immune response. Further validation of this novel therapeutic approach of applying α-Gal technology in in vivo models of bacterial infection is warranted.

Key Messages

• α-Gal-tagged aptamers lead to GAS opsonization with anti-Gal antibodies.

• α-Gal-tagged aptamers confer phagocytosis and killing of GAS cells by human phagocytes.

• α-Gal-tagged aptamers reduces replication of GAS in human blood.

• α-Gal-tagged aptamers may have the potential to be used as novel passive immunization drugs.

Keywords

Aptamer Galactose-α-1,3-galactosyl-β-1,4-N-acetyl-glucosamine α-Gal Anti-Gal Antibiotic therapy Drug development Antibodies Group A Streptococcus M protein Phagocytosis 

Notes

Acknowledgments

The authors would like to thank Drs. Igor Kojic (Loxbridge Research, London, UK), Dimitri van Simaeys, and Paul Hatala (both Altermune Technologies) for helpful discussions. We are grateful to Chelsea Stewart and Dr. Partho Ghosh (Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, CA) for providing recombinant M protein constructs. The authors are thankful to Dr. Malak Kotb (University of North Dakota School of Medicine and Health Sciences, Grand Forks, ND) and Dr. Bernard W. Beall (CDC, Atlanta, GA) for providing GAS strains for the study and Dr. Mark Walker (University of Queensland) for providing anti-M1 rabbit antiserum. The work of Dr. Iacomini was supported by NIH grant 1R01AI083459-06.

Author contributions

SAK, JHH, BH, and EL designed and conducted the experiments; SAK and VN wrote the manuscript; SAK, BH, RO, UG, CR, KBM, MW, and VN contributed to the study design. BH designed truncated aptamer variants. UG and JI provided critical research materials. SAK, MW, and VN directed the study.

Conflict of interest

The aptamer work was funded in full by Altermune Technologies, LLC (Irvine, CA). Several of the authors are employees, have executive roles and/or are consultants to Altermune Technologies, LLC with respect to their efforts to develop aptamers as therapeutic drugs.

Supplementary material

109_2015_1280_MOESM1_ESM.doc (1.2 mb)
ESM 1 (DOC 1.22 mb)

References

  1. 1.
    Chan M (2012) Antimicrobial resistance in the European Union and the world. Combating antimicrobial resistance: time for action Copenhagen, DenmarkGoogle Scholar
  2. 2.
    Prevention CfDCa (2013) Antibiotic resistance threats in the United States, 2013Google Scholar
  3. 3.
    Boucher HW, Talbot GH, Benjamin DK Jr, Bradley J, Guidos RJ, Jones RN, Murray BE, Bonomo RA, Gilbert D, Infectious Diseases Society of America (2013) 10 x '20 Progress–development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis 56:1685–1694CrossRefPubMedCentralPubMedGoogle Scholar
  4. 4.
    Pucci MJ, Bush K (2013) Investigational antimicrobial agents of 2013. Clin Microbiol Rev 26:792–821CrossRefPubMedCentralPubMedGoogle Scholar
  5. 5.
    Oleksiewicz MB, Nagy G, Nagy E (2012) Anti-bacterial monoclonal antibodies: back to the future? Arch Biochem Biophys 526:124–131CrossRefPubMedGoogle Scholar
  6. 6.
    Scully IL, Liberator PA, Jansen KU, Anderson AS (2014) Covering all the bases: preclinical development of an effective Staphylococcus aureus vaccine. Front Immunol 5:109CrossRefPubMedCentralPubMedGoogle Scholar
  7. 7.
    Ahmad TA, El-Sayed LH, Haroun M, Hussein AA, El Ashry el SH (2012) Development of immunization trials against Klebsiella pneumoniae. Vaccine 30:2411–2420CrossRefPubMedGoogle Scholar
  8. 8.
    Garcia-Quintanilla M, Pulido MR, McConnell MJ (2013) First steps towards a vaccine against Acinetobacter baumannii. Curr Pharm Biotechnol 14:897–902CrossRefPubMedGoogle Scholar
  9. 9.
    Priebe GP, Goldberg JB (2014) Vaccines for Pseudomonas aeruginosa: a long and winding road. Expert Rev Vaccines 13:507–519CrossRefPubMedGoogle Scholar
  10. 10.
    Ter Meulen J (2011) Monoclonal antibodies in infectious diseases: clinical pipeline in 2011. Infect Dis Clin North Amer 25:789–802CrossRefGoogle Scholar
  11. 11.
    Galili U, Mandrell RE, Hamadeh RM, Shohet SB, Griffiss JM (1988) Interaction between human natural anti-alpha-galactosyl immunoglobulin G and bacteria of the human flora. Infect Immun 56:1730–1737PubMedCentralPubMedGoogle Scholar
  12. 12.
    Galili U, Rachmilewitz EA, Peleg A, Flechner I (1984) A unique natural human IgG antibody with anti-alpha-galactosyl specificity. J Exp Med 160:1519–1531CrossRefPubMedGoogle Scholar
  13. 13.
    Galili U, Anaraki F, Thall A, Hill-Black C, Radic M (1993) One percent of human circulating B lymphocytes are capable of producing the natural anti-Gal antibody. Blood 82:2485–2493PubMedGoogle Scholar
  14. 14.
    Galili U (1993) Interaction of the natural anti-Gal antibody with alpha-galactosyl epitopes: a major obstacle for xenotransplantation in humans. Immunol Today 14:480–482CrossRefPubMedGoogle Scholar
  15. 15.
    Macher BA, Galili U (2008) The Galalpha1,3Galbeta1,4GlcNAc-R (alpha-Gal) epitope: a carbohydrate of unique evolution and clinical relevance. Biochim Biophys Acta 1780:75–88CrossRefPubMedCentralPubMedGoogle Scholar
  16. 16.
    Banerjee J, Nilsen-Hamilton M (2013) Aptamers: multifunctional molecules for biomedical research. J Mol Med 91:1333–1342CrossRefPubMedGoogle Scholar
  17. 17.
    Zimbres FM, Tarnok A, Ulrich H, Wrenger C (2013) Aptamers: novel molecules as diagnostic markers in bacterial and viral infections? BioMed Res Intl 2013:731516CrossRefGoogle Scholar
  18. 18.
    Sundaram P, Kurniawan H, Byrne ME, Wower J (2013) Therapeutic RNA aptamers in clinical trials. Eur J Pharm Sci 48:259–271CrossRefPubMedGoogle Scholar
  19. 19.
    Carapetis JR, Steer AC, Mulholland EK, Weber M (2005) The global burden of group A streptococcal diseases. Lancet Infect Dis 5:685–694CrossRefPubMedGoogle Scholar
  20. 20.
    Hamula CL, Le XC, Li XF (2011) DNA aptamers binding to multiple prevalent M-types of Streptococcus pyogenes. Analyt Chem 83:3640–3647CrossRefGoogle Scholar
  21. 21.
    Zuker M (2003) Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acid Res 31:3406–3415CrossRefPubMedCentralPubMedGoogle Scholar
  22. 22.
    Kikin O, D'Antonio L, Bagga PS (2006) QGRS Mapper: a web-based server for predicting G-quadruplexes in nucleotide sequences. Nucleic Acids Res 34:W676–W682CrossRefPubMedCentralPubMedGoogle Scholar
  23. 23.
    Cretin N, Iacomini J (2002) Immunoglobulin heavy chain transgenic mice expressing Galalpha(1,3)Gal-reactive antibodies. Transplantation 73:1558–1564CrossRefPubMedGoogle Scholar
  24. 24.
    Galili U, Anaraki F (1995) alpha-galactosyl (Galalpha1-3Galbeta1-4GlcNAc-R) epitopes on human cells: synthesis of the epitope on human red cells by recombinant primate α1,3galactosyltransferase expressed in E.coli. Glycobiology 5:775–782CrossRefPubMedGoogle Scholar
  25. 25.
    Kristian SA, Datta V, Weidenmaier C, Kansal R, Fedtke I, Peschel A, Gallo RL, Nizet V (2005) D-alanylation of teichoic acids promotes group a streptococcus antimicrobial peptide resistance, neutrophil survival, and epithelial cell invasion. J Bacteriol 187:6719–6725CrossRefPubMedCentralPubMedGoogle Scholar
  26. 26.
    Walker MJ, Hollands A, Sanderson-Smith ML, Cole JN, Kirk JK, Henningham A, McArthur JD, Dinkla K, Aziz RK, Kansal RG et al (2007) DNase Sda1 provides selection pressure for a switch to invasive group A streptococcal infection. Nat Med 13:981–985CrossRefPubMedGoogle Scholar
  27. 27.
    Aziz RK, Kotb M (2008) Rise and persistence of global M1T1 clone of Streptococcus pyogenes. Emerg Infect Dis 14:1511–1517CrossRefPubMedCentralPubMedGoogle Scholar
  28. 28.
    Hollingshead SK, Fischetti VA, Scott JR (1987) A highly conserved region present in transcripts encoding heterologous M proteins of group A streptococci. Infect Immun 55:3237–3239PubMedCentralPubMedGoogle Scholar
  29. 29.
    Oehmcke S, Shannon O, Morgelin M, Herwald H (2010) Streptococcal M proteins and their role as virulence determinants. Clin Chim Acta 411:1172–1180CrossRefPubMedGoogle Scholar
  30. 30.
    Smeesters PR, McMillan DJ, Sriprakash KS (2010) The streptococcal M protein: a highly versatile molecule. Trends Microbiol 18:275–282CrossRefPubMedGoogle Scholar
  31. 31.
    Crater DL, van de Rijn I (1995) Hyaluronic acid synthesis operon (has) expression in group A streptococci. J Biol Chem 270:18452–18458CrossRefPubMedGoogle Scholar
  32. 32.
    Unnikrishnan M, Cohen J, Sriskandan S (1999) Growth-phase-dependent expression of virulence factors in an M1T1 clinical isolate of Streptococcus pyogenes. Infect Immun 67:5495–5499PubMedCentralPubMedGoogle Scholar
  33. 33.
    Salvadori LG, Blake MS, McCarty M, Tai JY, Zabriskie JB (1995) Group A streptococcus-liposome ELISA antibody titers to group A polysaccharide and opsonophagocytic capabilities of the antibodies. J Infect Dis 171:593–600CrossRefPubMedGoogle Scholar
  34. 34.
    Dale JB (2008) Current status of group A streptococcal vaccine development. Adv Exper Med Biol 609:53–63CrossRefGoogle Scholar
  35. 35.
    Pestourie C, Tavitian B, Duconge F (2005) Aptamers against extracellular targets for in vivo applications. Biochimie 87:921–930CrossRefPubMedGoogle Scholar
  36. 36.
    Zipfel PF, Hallstrom T, Riesbeck K (2013) Human complement control and complement evasion by pathogenic microbes—tipping the balance. Mol Immunol 56:152–160CrossRefPubMedGoogle Scholar
  37. 37.
    McEnaney PJ, Parker CG, Zhang AX, Spiegel DA (2012) Antibody-recruiting molecules: an emerging paradigm for engaging immune function in treating human disease. ACS Chem Biol 7:1139–1151CrossRefPubMedCentralPubMedGoogle Scholar
  38. 38.
    Li J, Zacharek S, Chen X, Wang J, Zhang W, Janczuk A, Wang PG (1999) Bacteria targeted by human natural antibodies using α-Gal conjugated receptor-specific glycopolymers. Bioorg Med Chem 7:1549–1558CrossRefPubMedGoogle Scholar
  39. 39.
    Kaewsapsak P, Esonu O, Dube DH (2013) Recruiting the host's immune system to target Helicobacter pylori's surface glycans. ChemBioChem 14:721–726CrossRefPubMedCentralPubMedGoogle Scholar
  40. 40.
    Bertozzi CB, Bednarski MD (1992) A receptor-mediated immune response using synthetic glycoconjugates. J Am Chem Soc 114:5543–5546CrossRefGoogle Scholar
  41. 41.
    Krishnamurthy VM, Quinton LJ, Estroff LA, Metallo SJ, Isaacs JM, Mizgerd JP, Whitesides GM (2006) Promotion of opsonization by antibodies and phagocytosis of Gram-positive bacteria by a bifunctional polyacrylamide. Biomaterials 27:3663–3674PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Sascha A. Kristian
    • 1
    • 3
  • John H. Hwang
    • 2
    • 3
  • Bradley Hall
    • 1
  • Emma Leire
    • 3
  • John Iacomini
    • 5
  • Robert Old
    • 6
  • Uri Galili
    • 7
  • Charles Roberts
    • 1
    • 6
  • Kary B. Mullis
    • 1
  • Mike Westby
    • 1
    • 6
    Email author
  • Victor Nizet
    • 3
    • 4
    Email author
  1. 1.Altermune Technologies, LLCIrvineUSA
  2. 2.BS/MS Program, Division of Biological SciencesUniversity of California San Diego (UCSD)La JollaUSA
  3. 3.Department of PediatricsUniversity of California San Diego (UCSD)La JollaUSA
  4. 4.Skaggs School of Pharmacy and Pharmaceutical SciencesUniversity of California San Diego (UCSD)La JollaUSA
  5. 5.Sackler School of Biomedical Sciences Programs in Immunology and Genetics, Department of Development, Molecular and Chemical BiologyTufts University School of MedicineBostonUSA
  6. 6.Loxbridge ResearchThe Royal Institution of Great BritainLondonUK
  7. 7.Department of SurgeryUniversity of Massachusetts Medical SchoolWorcesterUSA

Personalised recommendations